TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has announced the co-formulation of ASC36, an amylin receptor agonist, and ASC35, a GLP-1R/GIPR dual agonist, both designed for once-monthly subcutaneous administration. The co-formulation demonstrated significant body weight reduction in preclinical studies and showed excellent stability, supporting its potential as a treatment for obesity. Ascletis plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, marking a significant step in its clinical development pipeline.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company focused on developing innovative therapies for metabolic diseases. The company utilizes proprietary technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create next-generation therapeutics.
Average Trading Volume: 8,837,254
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.34B
For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.